CN112494537A - Compound lithospermum itching relieving ointment, preparation method and application - Google Patents
Compound lithospermum itching relieving ointment, preparation method and application Download PDFInfo
- Publication number
- CN112494537A CN112494537A CN202011491764.7A CN202011491764A CN112494537A CN 112494537 A CN112494537 A CN 112494537A CN 202011491764 A CN202011491764 A CN 202011491764A CN 112494537 A CN112494537 A CN 112494537A
- Authority
- CN
- China
- Prior art keywords
- parts
- lithospermum
- compound
- itching relieving
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine composite medicaments, and particularly relates to a compound lithospermum itching relieving paste, a preparation method and application thereof, wherein the compound lithospermum itching relieving paste comprises the following raw material components in parts by weight, 5 parts of lithospermum, 1.5-2 parts of mint, 1.5-2 parts of fructus cnidii, 1.5-2 parts of fructus kochiae, 20-25 parts of propolis, 2-3 parts of borneol and 75 parts of olive oil or camellia oil; the compound lithospermum itching relieving cream is safe and harmless, ecological and environment-friendly, is convenient to process, is extracted and decocted by pure traditional Chinese medicines, does not contain components irritating to skin such as hormone and the like, and can effectively treat the papular urticaria.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine composite medicaments, and particularly relates to a compound lithospermum itching relieving ointment, a preparation method and application thereof.
Background
Papular urticaria is a disease named after symptom characteristics, also called as urticaria, lichen and infant lichen, is a delayed anaphylactic skin disease related to insect bites, is mostly seen in infants and children, is better seen in four limbs and trunk parts, is mostly seen in spring, summer and autumn, and is characterized by red wheal-like papules with round, oval or spindle shapes, blisters or bullae at the top end and pit marks of blood sucking insect bites, no blush around the pits, indefinite number, scattered distribution, clustering but not fusion, and infectious skin diseases such as impetigo, furuncle and the like caused by severe itching and skin tetany. The pathogeny is related to exogenous anaphylactic reaction of bedbugs, fleas, lice, mites, mosquitoes, scabies of dogs, tsutsugamushi, dermanyssus gallinae and midges biting as well as food and medicine anaphylactic reaction, and mainly the disease is caused to children allergic to the substance by injecting saliva after the arthropods bite the skin. At present, 1% of mint and calamine lotion and corticosteroid cream are used for itching relieving and inflammation diminishing treatment, the treatment time is long, the cure rate is low, and the lotion can be frequently and repeatedly attacked, and meanwhile, the 1% of mint and calamine lotion has an irritant effect on the skin.
Cortisone butyrate is a middle-acting steroid glucocorticoid, can inhibit local vasodilatation, can reduce the permeability of capillary vessels, inhibit inflammatory reaction caused by lymphokines, inhibit skin delayed allergy, has the effects of resisting inflammation, allergy, immunosuppression and the like, and has obvious anti-inflammatory effect on skin diseases caused by non-infection. It is mainly used for treating dermatosis such as allergic dermatitis, seborrheic dermatitis, eczema, and chronic simple lichen. Hydrocortisone butyrate ointment or cream which is currently circulated in the market is mostly single-component preparation, wherein the content of hydrocortisone butyrate is generally 0.1%, although the single application of the steroid glucocorticoid is effective, the disadvantage of the single application of the steroid glucocorticoid is that the side effects are more, such as skin thinning, muscle atrophy, acne, hirsutism, pigmentation and the like, wherein the side effects of the pigmentation are most troublesome, and the metabolism and absorption usually require 1-2 years.
Chinese patent application No. 201811251953.X discloses an ointment for papular urticaria, which comprises hydrocortisone butyrate serving as an active ingredient and paeonol serving as an active ingredient, wherein the ointment comprises 1.5 parts by weight of hydrocortisone butyrate, 23 parts by weight of paeonol and 1005-1070.5 parts by weight of an ointment matrix; the cream base comprises: 60-65 parts of glycerol, 20-30 parts of propylene glycol, 145-155 parts of vaseline, 95-105 parts of octadecanol, 95-105 parts of liquid paraffin, 20-30 parts of peregal O, 1.5-4.5 parts of citric acid, 0.5-1 part of sodium citrate and 568-574.5 parts of purified water. The addition of paeonol in the invention reduces the side effect of hydrocortisone butyrate, reduces the irritation of skin, and has obvious effects of relieving itching, relieving pain and reducing swelling; the pigmentation is obviously improved, and the special smell of the paeonol has the effects of repelling mosquitoes and expelling parasites, and the secondary sting allergy is reduced; the prepared paste does not contain preservative, but the preservative effect still meets the standard.
Disclosure of Invention
The compound lithospermum itching relieving ointment is safe, harmless, ecological, environment-friendly and convenient to process, adopts pure traditional Chinese medicines for extraction and decoction, does not contain components such as hormone and the like which irritate the skin, and can effectively treat the papular urticaria.
The invention relates to a compound lithospermum itching relieving paste which comprises the following raw material components in parts by weight, 5 parts of lithospermum, 1.5-2 parts of mint, 1.5-2 parts of fructus cnidii, 1.5-2 parts of fructus kochiae, 20-25 parts of propolis, 2-3 parts of borneol and 75 parts of olive oil or camellia oil; also comprises a component A, wherein the component A comprises 1.5-2 parts of wrinkled gianthyssop herb, 1.5-2 parts of argy wormwood leaf and 1.5-2 parts of dittany bark, or the component A comprises 1.5-2 parts of dahurian angelica root, 1.5-2 parts of amur corktree bark, 1.5-2 parts of honeysuckle flower and 1.5-2 parts of lavender;
preferably, the traditional Chinese medicine comprises the following raw materials, by weight, 5 parts of lithospermum, 1.5 parts of mint, 1.5 parts of fructus cnidii, 1.5 parts of fructus kochiae, 20 parts of propolis, 2 parts of borneol and 75 parts of olive oil or camellia oil; also comprises a component A, wherein the component A comprises 1.5 parts of wrinkled gianthyssop herb, 1.5 parts of argy wormwood leaf and 1.5 parts of dittany bark.
Preferably, the traditional Chinese medicine comprises the following raw material components, by weight, 5 parts of lithospermum, 2 parts of mint, 2 parts of fructus cnidii, 2 parts of fructus kochiae, 20 parts of propolis, 2 parts of borneol and 75 parts of olive oil or camellia oil; the traditional Chinese medicine composition also comprises a component A, wherein the component A comprises 2 parts of angelica dahurica, 2 parts of phellodendron, 2 parts of honeysuckle and 2 parts of lavender.
The invention provides a preparation method of compound lithospermum itching relieving paste, which comprises the steps of mixing lithospermum, mint, fructus cnidii, fructus kochiae and a component A, soaking in olive oil or camellia oil for a period of time, filtering, heating and decocting filtrate for a period of time, adding propolis and borneol, and cooling to obtain the compound lithospermum itching relieving paste.
Preferably, the soaking time is more than 2 months, and the sealing and light-shielding treatment is carried out.
Preferably, the temperature for heating and boiling the filtrate is 50 ℃.
The invention provides application of compound lithospermum itching relieving ointment in preparing a medicine for treating papular urticaria.
The compound lithospermum itching relieving ointment has the beneficial effects that the compound lithospermum itching relieving ointment is safe and harmless, ecological and environment-friendly, and convenient to process, is extracted and decocted by adopting pure traditional Chinese medicines, does not contain components which are irritant to skin, such as hormone and the like, and can effectively treat the papular urticaria.
The lithospermum erythrorhizon ointment is a non-hormone medicine and is more easily accepted by patients and family members.
Detailed Description
Example 1
A compound lithospermum itching relieving ointment comprises the following raw materials of 50g of lithospermum, 15 g of wrinkled gianthyssop herb, 15 g of mint, 15 g of folium artemisiae argyi, 15 g of cortex dictamni, 15 g of common cnidium fruit, 15 g of belvedere fruit, 750g of olive oil, 200 g of propolis and 20 g of borneol.
The preparation method comprises the following steps of,
1. mixing 50g of lithospermum, 15 g of wrinkled gianthyssop herb, 15 g of mint, 15 g of folium artemisiae argyi, 15 g of cortex dictamni, 15 g of fructus cnidii and 15 g of fructus kochiae, adding the mixture into 750g of olive oil, stirring the mixture evenly to ensure that the raw materials are fully mixed in the olive oil, and storing the mixture for 2 months in a sealed and dark place;
2. and (3) filtering: filtering the soaked materials, and filtering to obtain a lithospermum oil filtrate;
3. boiling with fire: adding the above radix Arnebiae oil filtrate into a container, controlling the temperature at 50 deg.C for a period of time, adding propolis, mixing, decocting for a period of time, adding Borneolum Syntheticum, cooling, and cooling to 20 deg.C to obtain compound radix Arnebiae itching relieving paste.
Example 2
Compared with the embodiment 1, the embodiment 2 is different from the embodiment 1 in that the traditional Chinese medicine comprises the following raw materials of 50g of lithospermum, 20 g of angelica dahurica, 20 g of phellodendron, 20 g of honeysuckle, 20 g of mint, 20 g of lavender, 20 g of broom cypress fruit, 20 g of fructus cnidii, 750g of camellia oil, 200 g of propolis and 20 g of borneol. The rest is the same as in example 1.
Experimental example 1
Selecting 72 cases of papular urticaria of children for pediatric diagnosis in a national hospital of Ningxiang city in 2019 from 5 months to 2019 and randomly dividing the urticaria into 36 cases of treatment groups, 19 cases of men and 17 cases of women, the ages of the treatment groups are 1.6-9.8 years, and the average (5.5 +/-2.04) years; the course of the disease is 1-6.5 days, and the average (3.7 +/-1.67) days. 36 control cases, 21 men and 15 women, the ages of which are 2.4-9.6 years, and the average (5.3 +/-2.15) years; the course of disease is 1-6.5 days, on average (3.5 +/-1.55 days).
The diagnosis standard refers to the diagnosis standard in dermatology diagnosis and treatment routine and clinical dermatology:
(1) it is good for children, and is common in spring to autumn;
(2) the skin lesion is a watery swelling spindle-shaped or oval red wheal with different sizes, a papule, a blister or a tension bullal can be arranged in the center, and the central skin lesion becomes hard after the wheal disappears quickly and is red or brown papule which is difficult to disappear for a long time;
(3) the disease is better at the extending sides of the trunk and the limbs, and is irregularly clustered but not fused;
(4) the subjective itching is severe;
(5) the rash subsides leaving behind pigmentation.
Inclusion and exclusion criteria
Inclusion criteria were:
(1) those who meet the criteria for the diagnosis of papular urticaria;
(2) the sex is not limited, and the age is 1-12 years old;
(3) the new eruption time is within 7 days, and the number of the new eruptions is 1-15;
(4) the legal guardian signs an informed consent.
Exclusion criteria:
(1) the review does not meet the inclusion criteria;
(2) patients with severe center of gravity, liver, kidney disease or hematological disorders;
(3) those allergic to the test drug ingredients;
(4) those receiving other medications during treatment;
(5) poor compliance, inability to take medicine on time or make a regular re-visit;
(6) those who have discontinued treatment due to adverse events.
Method of treatment
The treatment group is given compound radix Arnebiae itching relieving ointment (example 1) topically, 1 day and 2 times, and massaged with hands for 2min after being applied to and around rash part until the medicine is completely absorbed; the treatment course is 7 days. The control group is topically coated with halometasone cream for 2 times in 1 day; the application method and treatment course are the same as those of the treatment group. During the treatment period, people order a light diet and are prohibited to eat spicy and fishy stimulating foods; avoid contacting with substances which are easy to cause allergy such as insects, animal dander and the like. Such as the appearance of local pain, ulceration or adverse reactions such as chest distress, palpitation, etc., the test is allowed to abort.
Detection indexes are as follows: the number of wheal-like papules is taken as a detection index; after 1 week of treatment, the patients were retested and the regression of the number of wheal-like papules before and after treatment and the presence or absence of new eruptions were recorded.
The statistical method comprises the following steps: using SPSS20.0 statistical software, expressing the measured data by mean + -standard deviation (x + -s), and adopting t test; checking the counting data by a chi-square; differences of P <0.05 were statistically significant.
Results
Standard of therapeutic effect
And (3) healing: basically, the rash is completely removed, no new eruption exists, no pruritus exists, and pigmentation can be left;
the effect is shown: the rash subsides by more than 70 percent, no new eruption exists basically, and the pruritus is obviously relieved;
the method has the following advantages: the rash subsides by more than 50 percent, a little new rash still occurs, and the pruritus is partially relieved;
and (4) invalidation: the rash subsided less than 50% or remained unchanged, and new rash still occurred, and the pruritus was not relieved.
Total effective rate (cure + significant effect + effective)/total number of cases x 100%. The therapeutic index is (number of target lesions before treatment-number of target lesions after treatment)/number of target lesions before treatment × 100%.
The clinical efficacy of two groups of patients is compared with the total effective rate of 80.56% in the treatment group and 83.33% in the control group, and the comparison difference of the two groups of patients has no statistical significance (P >0.05), which is shown in Table 1.
Clinical efficacy comparison after treatment of two groups of patients
1 case (2.78%) of adverse reaction treatment group and 8 cases (22.22%) of control group have local slight erythema and desquamation, and the adverse reaction rate of the treatment group is obviously lower than that of the control group (P < 0.05). No serious adverse reactions were observed in both groups.
To summarize: the clinical curative effect of the compound lithospermum itching relieving ointment on treating the papular urticaria of children is equivalent to that of the halometasone emulsifiable paste, and the incidence rate of adverse reactions is obviously lower than that of the halometasone emulsifiable paste. The compound lithospermum itching relieving ointment is used as a pure herbal and non-hormonal medicine, has definite curative effect and good safety, and is more easily accepted by patients and families.
Those of ordinary skill in the art will understand that: the discussion of any embodiment above is meant to be exemplary only, and is not intended to intimate that the scope of the disclosure, including the claims, is limited to these examples; within the spirit of the present disclosure, features from the above embodiments or from different embodiments may also be combined, steps may be implemented in any order, and there are many other variations of different aspects of one or more embodiments in this application as described above, which are not provided in detail for the sake of brevity.
It is intended that the one or more embodiments of the present application embrace all such alternatives, modifications and variations as fall within the broad scope of the appended claims. Therefore, any omissions, modifications, substitutions, improvements, and the like that may be made without departing from the spirit and principles of one or more embodiments of the present disclosure are intended to be included within the scope of the present disclosure.
Claims (7)
1. The compound lithospermum itching relieving ointment is characterized by comprising the following raw materials, by weight, 5 parts of lithospermum, 1.5-2 parts of mint, 1.5-2 parts of fructus cnidii, 1.5-2 parts of fructus kochiae, 20-25 parts of propolis, 2-3 parts of borneol and 75 parts of olive oil or camellia oil; also comprises a component A, wherein the component A comprises 1.5-2 parts of wrinkled gianthyssop herb, 1.5-2 parts of argy wormwood leaf and 1.5-2 parts of dittany bark, or the component A comprises 1.5-2 parts of dahurian angelica root, 1.5-2 parts of amur corktree bark, 1.5-2 parts of honeysuckle flower and 1.5-2 parts of lavender.
2. The compound lithospermum itching relieving ointment as claimed in claim 1, which is characterized by comprising the following raw material components, by weight, 5 parts of lithospermum, 1.5 parts of mint, 1.5 parts of fructus cnidii, 1.5 parts of fructus kochiae, 20 parts of propolis, 2 parts of borneol and 75 parts of olive oil or camellia oil; also comprises a component A, wherein the component A comprises 1.5 parts of wrinkled gianthyssop herb, 1.5 parts of argy wormwood leaf and 1.5 parts of dittany bark.
3. The compound lithospermum itching relieving ointment as claimed in claim 1, which is characterized by comprising the following raw material components, by weight, 5 parts of lithospermum, 2 parts of mint, 2 parts of fructus cnidii, 2 parts of fructus kochiae, 20 parts of propolis, 2 parts of borneol and 75 parts of olive oil or camellia oil; the traditional Chinese medicine composition also comprises a component A, wherein the component A comprises 2 parts of angelica dahurica, 2 parts of phellodendron, 2 parts of honeysuckle and 2 parts of lavender.
4. A method for preparing compound radix Arnebiae itching relieving paste as claimed in any one of claims 1-3, wherein radix Arnebiae, herba Menthae, fructus Cnidii, Kochiae fructus and component A are mixed, soaked in oleum Olivarum or oleum Camelliae Japonicae for a period of time, filtered, the filtrate is heated and decocted for a period of time, propolis and Borneolum Syntheticum are added, and cooling is carried out to obtain compound radix Arnebiae itching relieving paste.
5. The method for preparing the compound lithospermum itching relieving ointment as claimed in claim 4, wherein the soaking time is more than 2 months, and the compound lithospermum itching relieving ointment is sealed and protected from light.
6. The method for preparing the compound lithospermum itching-relieving ointment as claimed in claim 4, wherein the temperature for heating and boiling the filtrate is 50 ℃.
7. Use of the compound lithospermum itching relieving ointment as defined in any one of claims 1 to 3 in the preparation of a medicament for treating papular urticaria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011491764.7A CN112494537A (en) | 2020-12-16 | 2020-12-16 | Compound lithospermum itching relieving ointment, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011491764.7A CN112494537A (en) | 2020-12-16 | 2020-12-16 | Compound lithospermum itching relieving ointment, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112494537A true CN112494537A (en) | 2021-03-16 |
Family
ID=74973014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011491764.7A Pending CN112494537A (en) | 2020-12-16 | 2020-12-16 | Compound lithospermum itching relieving ointment, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112494537A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943672A (en) * | 2005-10-08 | 2007-04-11 | 周小明 | A Chinese traditional medicinal composition for treatment of dermatosis and its preparation method |
| CN102861272A (en) * | 2012-08-23 | 2013-01-09 | 景颖 | Preparation method of traditional Chinese medicine wet issue for treating urticaria papulosa |
| CN103565981A (en) * | 2013-11-25 | 2014-02-12 | 马建国 | Tincture for curing urticaria papulosa and preparation method of tincture |
-
2020
- 2020-12-16 CN CN202011491764.7A patent/CN112494537A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943672A (en) * | 2005-10-08 | 2007-04-11 | 周小明 | A Chinese traditional medicinal composition for treatment of dermatosis and its preparation method |
| CN102861272A (en) * | 2012-08-23 | 2013-01-09 | 景颖 | Preparation method of traditional Chinese medicine wet issue for treating urticaria papulosa |
| CN103565981A (en) * | 2013-11-25 | 2014-02-12 | 马建国 | Tincture for curing urticaria papulosa and preparation method of tincture |
Non-Patent Citations (2)
| Title |
|---|
| 白兴华: "《慢性难治性疾病穴位贴敷疗法》", 30 April 2001, 科学技术文献出版社 * |
| 罗宏宾等: "紫草膏治疗儿童丘疹性荨麻疹36例", 《浙江中西医结合杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105168090A (en) | Gromwell ointment and preparation method thereof | |
| AU2004222357A1 (en) | Homeopathic formulations useful for treating pain and/or inflammation | |
| DE3705151A1 (en) | WARTS | |
| CN108938759B (en) | Medicine or daily chemical product composition for treating hand-foot syndrome and preparation method and application thereof | |
| DE69730214T2 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF HERPES SIMPLEX | |
| CN108578465A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN111803603A (en) | A medicinal preparation for treating dermatoses and bacterial virus caused by mosquito bite | |
| CN112494537A (en) | Compound lithospermum itching relieving ointment, preparation method and application | |
| CN105148230B (en) | Medicine for treating cancer pain and preparation method thereof | |
| CN110812295B (en) | Infantile tinea-repairing cream | |
| CN114146051A (en) | Chinese medicinal gel for promoting granulation and healing ulcer, and its preparation method | |
| US20060177527A1 (en) | Methods and compositions for treating psoriasis | |
| CN102247533A (en) | External drug for treating trauma | |
| CN109999111A (en) | A kind of pharmaceutical composition and preparation method thereof for treating acne | |
| Telange et al. | Herbal bioactives for treating infectious skin diseases | |
| CN110123931A (en) | It is a kind of to treat dermopathic pure Chinese medicine ointment and its preparation process | |
| CN113289026B (en) | Compound cortex phellodendri composition, compound cortex phellodendri spray preparation, preparation method and application | |
| CN105560837A (en) | Drug for treating skin injuries and preparation method thereof | |
| CN113855753B (en) | Medicament for treating monkey trauma and preparation method thereof | |
| EP2709606B1 (en) | Compositions containing resveratrol and essential oil of cloves for the treatment of itching | |
| CN107617009B (en) | Compound Chinese herbal medicine external preparation for treating rabbit skin folliculitis | |
| CN109091535B (en) | Pharmaceutical composition for treating mosquito bite dermatitis and preparation process and application thereof | |
| CN106421641A (en) | Traditional Chinese medicine composition and preparation for treating anorectal diseases | |
| CN113318072A (en) | Compound realgar ointment for treating herpes zoster and preparation method thereof | |
| CA3161854A1 (en) | Homeopathic topical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210316 |